clinical, neuroimaging and DNA assessments: Selected assessments, including evaluation of treatment response to specific antipsychotic drugs, will be performed at follow-up visits after 1, 3 and 5 years
Study summary
Five collaborating sites in France will study the broad spectrum of schizophrenia in children and adolescents. Patients will be studied with diagnostic interviews, developmental histories, dimensional clinical ratings, comprehensive cognitive assessments, neuroimaging and DNA (copy number variant) analyses (in families and patients who agree), and follow-up of course of illness, cognitive status and treatment response to specific antipsychotic drugs. The goal of the study is to test a prior hypothesis about clinical subgroups in this population and to test whether these subgroups predict antipsychotic medication response.
Eligibility
Sex
ALL
Min age
7 Years
Max age
20 Years
Healthy volunteers
Accepted
Inclusion Criteria for the Patient:
1. Children and young adults ages 7-20 years with age of onset of psychotic disorder between 7-17 years.
2. Hospitalized or seen for out-patient treatment for a psychotic episode, acute or chronic.
3. DSM-V diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, psychotic disorder not otherwise specified, or major depressive episode with psychotic features.
4. Written informed consent signed by the parents or the individual(s) with legal parental authority, and by the minor patient if his/her condition permits.
5. Written informed consent signed by the patient if he/she is a major, after clinical stabilization (not delusional).
6. Has health insurance coverage from Social Security (France) (not AME coverage).
Inclusion Criteria for parents or siblings wishing to participate in the genetic part of the study :
1. Parents : no specific criteria.
2. Siblings : siblings are eligible to participate if there are at least two first-degree relatives with psychotic disorders (including the patient) in the family.
3. Written informed consent for the genetic part of the study signed by any participating parents and siblings.
4. Has health insurance coverage from Social Security (France) (not AME coverage).
Exclusion Criteria:
1. Moderate or severe intellectual deficiency (IQ \< 50).
2. Psychoses judged to be secondary to medical illness, medication effects or drugs of abuse.
3. Diagnosis of bipolar disorder.
4. Patients who are under legal guardianship.
5. For the neuroimaging part of the study only : any contraindications to Magnetic Resonance Imaging.
Primary outcome measure(s)
Lifetime Dimensions of Psychosis Scale-Child and Adolescent Version — 4 months Symptoms are rated for lifetime duration and for severity during the worst two-week period.
Number of participants assigned to each of four clinical clusters derived by cluster analysis from clinical and developmental ratings on this scale as previously described.
Trial sites (6)
Facility
City
Region
Status
Fondation Vallée, Gentilly
Gentilly
France
Not Yet Recruiting
CHRU de Lille
Lille
France
Not Yet Recruiting
CHU de Nice
Nice
France
Not Yet Recruiting
Pitié Salpétrière
Paris
France
Recruiting
CHU de Rouen
Rouen
France
Not Yet Recruiting
CHU de Rouvray
Rouen
France
Not Yet Recruiting
More Assistance Publique - Hôpitaux de Paris trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.